Integra LifeSciences Holdings (IART)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 6.62% | 9.11% | 11.62% | 14.54% | 15.13% | 14.58% | 14.03% | 13.12% | 14.39% | 27.51% | 38.97% | 49.69% | 64.61% | 64.60% | 63.92% | 64.29% | 64.53% | 64.45% | 64.10% | 64.31% |
| Operating profit margin | 7.50% | 9.63% | 12.17% | 15.18% | 15.87% | 15.09% | 14.52% | 14.08% | 12.84% | 12.53% | 12.81% | 11.30% | 11.49% | 10.18% | 4.23% | 6.04% | 6.35% | 6.27% | 9.38% | 8.24% |
| Pretax margin | 5.45% | 7.82% | 10.48% | 13.53% | 14.21% | 13.26% | 12.73% | 12.36% | 13.98% | 13.20% | 12.80% | 10.89% | 7.10% | 6.12% | 0.90% | 3.19% | 4.07% | 3.97% | 6.67% | 5.12% |
| Net profit margin | 4.56% | 6.77% | 8.79% | 11.38% | 11.99% | 11.38% | 10.94% | 10.37% | 11.01% | 14.15% | 13.66% | 12.41% | 10.16% | 4.27% | -0.26% | 1.82% | 3.40% | 4.10% | 6.95% | 5.78% |
Integra Lifesciences Holdings Corp has shown some fluctuations in its profitability ratios over the past eight quarters. The gross profit margin has ranged from a low of 57.39% in Q4 2023 to a high of 62.29% in Q4 2022, indicating some variability in the company's ability to control its cost of goods sold.
Similarly, the operating profit margin has ranged from 7.23% in Q4 2023 to 15.34% in Q4 2022, suggesting fluctuations in the company's efficiency in managing operating expenses and generating profits from its core business operations.
The pretax margin has shown a similar trend, fluctuating from 5.26% in Q4 2023 to 13.73% in Q4 2022. This indicates variability in the company's ability to control non-operating expenses and generate profits before taxes.
Lastly, the net profit margin has ranged from 4.39% in Q4 2023 to 11.59% in Q4 2022, reflecting fluctuations in the company's ability to generate profits after accounting for all expenses, including taxes. Overall, it appears that Integra Lifesciences Holdings Corp's profitability ratios have experienced some fluctuations over the past eight quarters, which may warrant further investigation into the underlying factors driving these changes.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 2.95% | 3.83% | 4.81% | 6.12% | 6.14% | 6.02% | 5.88% | 5.79% | 5.21% | 5.08% | 5.19% | 4.14% | 4.19% | 3.90% | 1.67% | 2.57% | 2.84% | 2.74% | 4.13% | 3.67% |
| Return on assets (ROA) | 1.79% | 2.70% | 3.47% | 4.59% | 4.64% | 4.54% | 4.43% | 4.26% | 4.47% | 5.73% | 5.54% | 4.55% | 3.70% | 1.64% | -0.10% | 0.77% | 1.52% | 1.79% | 3.07% | 2.58% |
| Return on total capital | 4.44% | 5.57% | 6.86% | 8.45% | 8.49% | 8.06% | 7.93% | 7.85% | 8.62% | 8.53% | 8.67% | 7.17% | 5.65% | 5.29% | 2.58% | 3.73% | 4.36% | 4.24% | 5.78% | 5.08% |
| Return on equity (ROE) | 4.27% | 6.39% | 7.80% | 10.26% | 10.01% | 10.03% | 10.01% | 9.69% | 10.04% | 13.26% | 13.05% | 11.12% | 8.84% | 4.04% | -0.26% | 1.98% | 3.54% | 4.33% | 7.10% | 5.91% |
Integra Lifesciences Holdings Corp's profitability ratios indicate a fluctuating performance over the past eight quarters. The Operating Return on Assets (Operating ROA) has shown a declining trend from 6.12% in Q1 2023 to 2.95% in Q4 2023. This suggests that the company's ability to generate profits from its assets used in operations has weakened over time.
Similarly, the Return on Assets (ROA) has also decreased steadily from 4.59% in Q1 2023 to 1.79% in Q4 2023, indicating a decline in the overall profitability of the company relative to its total assets. This downward trend may raise concerns about the company's efficiency in generating earnings from its asset base.
However, the Return on Total Capital and Return on Equity (ROE) metrics show a similar pattern of fluctuation but with higher levels of profitability compared to the ROA ratios. The Return on Total Capital has ranged from 3.61% to 7.36% over the eight quarters, while the ROE has fluctuated between 4.27% and 10.26% during the same period.
Overall, while the company's profitability ratios have shown inconsistent performance, the Return on Equity (ROE) highlights Integra Lifesciences Holdings Corp's ability to generate profits for its shareholders' equity, albeit with some variability. Investors and analysts may need to further investigate the factors driving the fluctuations in profitability to assess the company's financial health accurately.